



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: SAKAMOTO et al. Examiner: Unknown
Serial No.: 10/501,801 Group Art Unit: Unknown
Filed: July 20, 2004 Docket: 08279.0770USWO
Title: IMPROVEMENT IN THE PRODUCTION OF IMIDAZOLE DERIVATIVES AND NOVEL
INTERMEDIATES OF THE DERIVATIVES

CERTIFICATE UNDER 37 CFR 1.8:

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail, with sufficient postage, in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on October 12, 2004.

By: 

Name: Sarah Dannecker

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450




Sir:

We are transmitting herewith the attached:

- ☒ Transmittal Sheet in duplicate containing Certificate of Mailing
- ☒ Information Disclosure Statement, Form 1449, 5 Reference(s)
- ☒ Return postcard

Please consider this a PETITION FOR EXTENSION OF TIME for a sufficient number of months to enter these papers or any future reply, if appropriate. Please charge any additional fees or credit overpayment to Deposit Account No. 13-2725. A duplicate of this sheet is enclosed.

MERCHANT & GOULD P.C.
P.O. Box 2903, Minneapolis, MN 55402-0903
612.332.5300

By: 
Name: Douglas P. Mueller
Reg. No. 30,300
DPM/sbd



DOCKET NOTIFICATION SLIP

TO: PATENT DOCKETING

Applicant: SAKAMOTO et al.
Title: IMPROVEMENT IN THE PRODUCTION OF IMIDAZOLE DERIVATIVES AND
NOVEL INTERMEDIATES OF THE DERIVATIVES
Serial No: 10/501,801
Filed: July 20, 2004
Docket: 08279.0770USWO
Due Date: N/A

- ☒ Transmittal Sheet in duplicate containing Certificate of Mailing
- ☒ Information Disclosure Statement, Form 1449, 5 Reference(s)
- ☒ Return postcard

Date of Deposit: October 12, 2004

DPM/sbd



10/501,801

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	SAKAMOTO et al.	Examiner:	Unknown
Serial No.:	10/501,801	Group Art Unit:	Unknown
Filed:	July 20, 2004	Docket No.:	08279.0770USWO
Title:	IMPROVEMENT IN THE PRODUCTION OF IMIDAZOLE DERIVATIVES AND NOVEL INTERMEDIATES OF THE DERIVATIVES		

CERTIFICATE UNDER 37 CFR 1.8:

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail, with sufficient postage, in an envelope addressed to: Commissioner for Patents, Mail Stop Amendment, P.O. Box 1450, Alexandria, VA 22313-1450 on October 12, 2004.

By: 

Name: Sarah Dannecker

INFORMATION DISCLOSURE STATEMENT (37 C.F.R. § 1.97(b))

Mail Stop Amendment

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Dear Sir:

With regard to the above-identified application, the items of information listed on the enclosed Form 1449 are brought to the attention of the Examiner.

This statement should be considered because it is submitted within three months of the filing date of the above-identified application, which is not an application under 37 C.F.R. § 1.53(d). Accordingly, no fee is due for consideration of the items listed on the enclosed Form 1449.

A copy of any foreign patent document or "Other Document" listed on the Form 1449 is enclosed, in accordance with 37 C.F.R. § 1.98(a)(2). Because this application was filed after June 30, 2003, copies of the U.S. Patents and U.S. patent publications listed on the enclosed Form 1449 are not provided.

No representation is made that a reference is "prior art" within the meaning of 35 U.S.C. §§ 102 and 103 and Applicants reserve the right, pursuant to 37 C.F.R. § 1.131 or otherwise, to establish that the reference(s) are not "prior art." Moreover, Applicants do not represent that a

reference has been thoroughly reviewed or that any relevance of any portion of a reference is intended.

Consideration of the items listed is respectfully requested. Pursuant to the provisions of M.P.E.P. 609, it is requested that the Examiner return a copy of the attached Form 1449, marked as being considered and initialed by the Examiner, to the undersigned with the next official communication.


Please charge any additional fees or credit any overpayment to Deposit Account No. 13-2725.




Respectfully submitted,

MERCHANT & GOULD P.C.
P.O. Box 2903
Minneapolis, Minnesota 55402-0903
(612) 332-5300

Dated: October 12, 2004

By: 
Douglas P. Mueller
Reg. No. 30,300

DPM/sbd

FORM 1440a  INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (Use several sheets if necessary)	Docket Number: 08279.0770USWO	Application Number: 10/501,801
	Applicant: SAKAMOTO et al.	
	Filing Date: July 20, 2004	Group Art Unit: Unknown

U.S. PATENT DOCUMENTS						
EXAMINER INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	6,100,264	08/2000	Aloup et al.			

FOREIGN PATENT DOCUMENTS							
	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	93/12107	06/1993	WIPO				
	95/06037	03/1995	WIPO				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
		Synthesis (1988); No. 9: 735-739
		Vollinga et al., "A New Potent and Selective Histamine H ₃ Receptor Agonist, 4-(1 <i>H</i> -Imidazol-4-ylmethyl)piperidine", Journal of Medicinal Chemistry (1994); 37: 332-333
		Harusawa et al., "An Efficient and Convenient Synthesis of 4-Vinylimidazoles Using Novel Horner-Wadsworth-Emmons (HWE) Reagent: Synthetic Studies Toward Novel Histamine H ₃ -Ligands", Synthesis (2002); No. 8: 1072-1078

23552
PATENT TRADEMARK OFFICE

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	